BioVersys AG to Present at the H. C. Wainwright BioConnect Virtual Conference

Basel, Switzerland. January 07, 2021, 2pm CEST

BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today that Marc Gitzinger, Chief Executive Officer at BioVersys, will present a company overview and update on the investment opportunity at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand beginning on Monday January 10 at 7:00am Eastern Standard Time (EST). Management of BioVersys will also host investor meetings January 10-13, 2022.

Conference: H.C. Wainwright Global BioConnect Virtual Conference

Format: On-demand recorded corporate presentation

Date: January 10, 2022 from 7:00 am Eastern Standard Time